Floatz logo

ava6103

Cervical Adenosquamous Carcinoma

Avacta Life Sciences LtdPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Cervical Adenosquamous Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Uganda Cancer Institute
Phase 2BB
PEGFILGRASTIM
National Cancer Institute (NCI)
Phase 2B
FILGRASTIM
National Cancer Institute (NCI)
Phase 2B
Hycamtin
National Cancer Institute (NCI)
Phase 2B
Veliparib
National Cancer Institute (NCI)
Phase 2B
FERUMOXTRAN 10
National Cancer Institute (NCI)
Phase 1/2CCC
Axalimogene Filolisbac
Advaxis, Inc.
Phase 1CC
Cetuximab
Gynecologic Oncology Group
Phase 1CC

Same molecule, other indications

ava6103 is also rated in:

cervical adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
gastroesophageal junction adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →